MedTrace Logo

[18F]-AraG PET Imaging in LA HNSCC

NCT07168785 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-09-11

No results posted yet for this study

Summary

This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

[18F]-AraG radiotracer

\[18F\]-AraG radiotracer, which occurs on the first and sixteenth day of treatment.

DRUG

Chemotherapy

Concurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.

DEVICE

Radiotherapy

Concurrent chemoradiotherapy (CRT) of 70Gy of radiation dose in 33 fractions.

Sponsors & Collaborators

  • CellSight Technologies, Inc.

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • Mark Langer · Indiana University Simon Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-06-30
Completion
2027-10-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168785 on ClinicalTrials.gov